New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - iobenzamic acid 500mg - capsule - 500 mg - active: iobenzamic acid 500mg

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

biotis life science pty ltd - glyphosate present as the isopropylamine salt - aqueous concentrate - glyphosate present as the isopropylamine salt glycine active 510.0 g/l - herbicide - agricultural area - general | almond | aquatic weed control | avocado plantation | banana plantation | blueberry | calomba daisy - african boxthorn | african lovegrass | amaranth - suppression | amsinckia | annual or wimmera ryegrass | annual phalaris | artichoke thistle | australian bluebell - w. gracilis | bamboo (bambusa spp.) | barbed wire grass | barley grass | barnyard grass or water grass | bent grass - agrostis capillaris | bent grass - agrostis tenuis | bitou bush or boneseed | black speargrass | blackberry | bladder ketmia | blady grass | boggabri weed | bracken | brome - seedling | brome grass - bromus unioloides | brown beetle grass - diplachne spp. | californian thistle | calomba daisy | caltrop - tribulis terrestis | caltrop or yellow vine - suppression | canary grass | capeweed | carpet grass - suppression | cat's ear or flatweed | cat's ears or flatweeds | chickweed | chinese scrub | cobbler's pegs | cocksfoot | common couch | common fumitory | common reed or phragmites | common sowthistle - suppression | common storksbill | crofton weed | cudweed - gnaphalium luteo-album | cumbungi | curled dock - seedling | dock | doubl

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - sofosbuvir, quantity: 400 mg; ledipasvir acetone solvate, quantity: 95.9 mg (equivalent: ledipasvir, qty 90 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; silicon dioxide; magnesium stearate; croscarmellose sodium; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; polyvinyl alcohol; macrogol 3350 - harvoni (ledipasvir/sofosbuvir fixed-dose combination) is indicated for the treatment of chronic hepatitis c (chc) infection in adults. (see precautions and clinical trials sections for information on the available data for hcv patients of each genotype, see dosage and administration section for recommended regimens and treatment durations for different patient subgroups).

Kenya - English - Pharmacy and Poisons Board

mylan laboratories limited mylan laboratories limited, plot no.564/a/22, - sofosbuvir and velpatasvir - tablet - each tablet contains: sofosbuvir and velpatasvir… - direct acting antivirals

Kenya - English - Pharmacy and Poisons Board

mylan laboratories limited mylan laboratories limited. plot no.564/a/22, - daclatasvir and sofosbuvir film-coated tablets 60… - film-coated tablet - each film-coated tablet contains: daclatasvir… - daclatasvir

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - sofosbuvir; velpatasvir - tablet - 400mg ; 100mg

Kenya - English - Pharmacy and Poisons Board

mylan laboratories limited mylan laboratories limited, plot no.564/a/22, - ledipasvir/ sofosbuvir - tablet - each tablet contains: ledipasvir/ sofosbuvir 90… - sofosbuvir and ledipasvir

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

natco pharma limited-pharma division - sofosbuvir, velpatasvir - tablets film-coated - 400mg+ 100mg

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - velpatasvir, quantity: 100 mg; sofosbuvir, quantity: 400 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; copovidone; silicified microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; macrogol 4000; polyvinyl alcohol - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection (genotype 1, 2, 3, 4, 5 or 6) in adults and paediatric patients 12 years of age and older and weighing 30 kg or more.,(see 4.2 dose and method of administration section for the recommended regimens for different patient subgroups).